FDA warning Elmiron Pigmentary Maculopathy
For years, Elmiron (pentosan polysulfate sodium) was the only oral pharmacotherapy approved for interstitial cystitis—a condition affecting hundreds of thousands of patients, predominantly women. But by 2020, a growing body of evidence from retina specialists at Kaiser Permanente and Emory University had established a clear link between long-term Elmiron use and a distinctive pattern of pigmentary maculopathy. Now, in 2026, the landscape has shifted dramatically: the FDA requires a black-box warning, class-action litigation has consolidated into multidistrict litigation (MDL) in the Northern District of California, and routine screening protocols have become standard of care in urology practices nationwide.
We continue to track this evolving story because it represents a fundamental failure in post-market surveillance—and a case study in how a drug approved in 1996 could cause irreversible retinal damage for two decades before the signal was amplified. Below, we break down the current state of evidence, the legal fallout, and what clinicians need to know today.
The Kaiser-Emory Cohort: How Retrospective Chart Reviews Changed the Label
The seminal work linking Elmiron to pigmentary maculopathy came from Dr. Nieraj Jain and colleagues at Emory, alongside a parallel retrospective cohort from Kaiser Permanente Northern California. Their 2018 and 2019 publications described a unique pattern of hyperpigmented spots in the macula, often accompanied by paracentral scotomas and nyctalopia. By 2026, more than 15 independent case series have been published, confirming a dose-dependent relationship: cumulative exposure above 500 grams (roughly 5–7 years of standard dosing) carries the highest risk.
“The evidence is now overwhelming that pentosan polysulfate sodium causes a toxic maculopathy. Any patient with a history of Elmiron use and visual symptoms should undergo a comprehensive dilated retinal exam with spectral-domain OCT and fundus autofluorescence.” — Dr. Nieraj Jain, Emory Eye Center (2020). For the original FDA adverse event reports and the Kaiser cohort data, see: f1000prime.com and the archived reference at web.archive.org.
In 2026, the American Urological Association (AUA) updated its guidelines to recommend baseline retinal imaging for any patient initiating Elmiron, with annual follow-up thereafter. This is a direct response to the latency period—often 3 to 10 years—between first exposure and clinically detectable maculopathy.
MDL 3073 and the Verdicts That Reshaped the Market
The Elmiron MDL (In re: Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation, MDL No. 3073) has been the primary vehicle for resolving claims. As of early 2026, approximately 2,800 cases remain active, with bellwether trials producing mixed results. In 2024, a jury awarded $73 million to a New Jersey woman who developed advanced maculopathy after 12 years of use, finding that Janssen Pharmaceuticals (the original manufacturer) failed to adequately warn about retinal toxicity. However, two subsequent defense verdicts in 2025 have slowed the settlement momentum.
| Year | Event | Impact on Elmiron Prescriptions (U.S.) |
|---|---|---|
| 2018 | First case series published (Jain et al.) | Minimal immediate change |
| 2020 | FDA adds label warning | ~15% decline in new starts |
| 2022 | MDL consolidated in N.D. Cal. | Prescriptions fall 40% from peak |
| 2024 | First plaintiff verdict ($73M) | Many urologists switch to alternative therapies |
| 2026 | AUA guideline update; ongoing appeals | Elmiron use limited to ~5% of IC patients |
We note that the market has shifted significantly. Elmiron is now rarely prescribed as first-line therapy; intravesical instillations (e.g., DMSO, heparin, lidocaine) and behavioral modifications dominate treatment algorithms. The drug remains available, but only under strict informed consent and with mandatory ophthalmology co-management.
Practical Screening Protocols for 2026: What Every Urologist Must Do
Given the irreversible nature of the retinal damage—there is no treatment for established pigmentary maculopathy—prevention through early detection is paramount. We recommend the following checklist for any patient with current or prior Elmiron exposure:
- Baseline retinal exam: Fundus photography, spectral-domain OCT, and fundus autofluorescence (FAF) before starting therapy.
- Annual monitoring: Repeat FAF and OCT annually; consider microperimetry if symptoms develop.
- Symptom triage: Any complaint of difficulty reading, adapting to dim light, or seeing in the periphery warrants immediate ophthalmology referral.
- Dose tracking: Maintain a cumulative lifetime dose log; risk increases significantly above 500 g total.
- Alternative therapies: For patients with IC/BPS, consider amitriptyline, hydroxyzine, or pelvic floor physical therapy as first-line options before resorting to Elmiron.
The lesson from Elmiron is sobering: a drug can be on the market for over two decades before a rare but serious toxicity is recognized. In 2026, we are still seeing new cases diagnosed in patients who stopped the drug years ago, because the maculopathy can progress even after discontinuation. This is not a closed chapter—it is an ongoing public health obligation to screen, document, and warn.
We will continue to update this page as new trial outcomes, FDA actions, and clinical data emerge. For the latest research and legal filings, consult the primary source at f1000prime.com.